Peoples Financial Services CORP. Has $3.78 Million Holdings in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 25th, 2023

Peoples Financial Services CORP. lowered its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,592 shares of the biopharmaceutical company’s stock after selling 1,060 shares during the period. Pfizer makes up approximately 1.8% of Peoples Financial Services CORP.’s holdings, making the stock its 13th biggest position. Peoples Financial Services CORP.’s holdings in Pfizer were worth $3,777,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RB Capital Management LLC lifted its position in shares of Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. lifted its position in shares of Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank lifted its position in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC lifted its position in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its position in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the last quarter. Institutional investors and hedge funds own 67.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PFE shares. Jefferies Financial Group started coverage on Pfizer in a research report on Monday, March 6th. They set a “hold” rating and a $43.00 price objective for the company. UBS Group lowered their price target on Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Morgan Stanley lowered their price target on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, April 10th. Daiwa Capital Markets lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target on the stock. in a research note on Thursday, May 11th. Finally, StockNews.com started coverage on Pfizer in a research note on Thursday, May 18th. They set a “buy” rating on the stock. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $47.33.

Pfizer Trading Down 1.1 %

PFE stock opened at $38.30 on Friday. Pfizer Inc. has a 1-year low of $36.17 and a 1-year high of $54.93. The firm has a market cap of $216.22 billion, a P/E ratio of 7.54, a P/E/G ratio of 1.27 and a beta of 0.64. The business’s 50 day moving average is $38.71 and its 200-day moving average is $42.68. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.23. The company had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The company’s revenue was down 28.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 EPS. Equities analysts anticipate that Pfizer Inc. will post 3.35 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 4.28%. The ex-dividend date is Thursday, July 27th. Pfizer’s payout ratio is currently 32.28%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Friday, May 5th. The shares were acquired at an average cost of $38.42 per share, with a total value of $38,420.00. Following the acquisition, the director now directly owns 5,000 shares of the company’s stock, valued at $192,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is owned by company insiders.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.